TITLE

Underuse of Wide Excision for Primary Cutaneous Melanoma in the United States

AUTHOR(S)
Haigh, Philip I.; Urbach, David R.
PUB. DATE
November 2004
SOURCE
American Surgeon;Nov2004, Vol. 70 Issue 11, p942
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Three randomized trials support wide excision (VVEX) for primary cutaneous melanoma. The objective was to evaluate WEX use for melanoma in the United Slates. Patients with localized melanoma were identified from the Surveillance, Epidemiology and End Results database between 1988 and 1997. Associations between predictor variables and WEX compared to biopsy alone were evaluated using logistic regression. Of 8,268 patients identified, 74.9 per cent had WEX, whereas 25.1 per cent had biopsy alone. WEX use peaked in 1990 at 81.6 per cent and was lowest in 1995 at 69.8 per cent. Overall, WEX use decreased over time. WEX use was independently associated with Breslow thickness (odds ratio lOR] per 1-mm depth of invasion 1.4, 95 per cent confidence interval [CI] 1.3, 1.5), and was inversely related to patient age (OR per 10 years of age 0.93; 95% CI 0.90, 0.96). As compared with the time period 1988 to 1990, WEX use declined during 1991 to 1993 (OR 0.71, 95% CI 0.60-0.83) and from 1994 to 1997 (OR 0.65; 95% CI 0.57-0.75). Many patients with localized melanoma undergo biopsy alone without a WEX. Use of WEX is associated with thicker melanomas and younger patients. Use of WEX has decreased over time, despite results from three randomized trials supporting its use.
ACCESSION #
15109142

 

Related Articles

  • Assessing Malignant Melanoma: A Case Study. Khachemoune, Amor; Ehrsam, Eric // Dermatology Nursing;Jun2005, Vol. 17 Issue 3, p188 

    Good history and close physical examination with high index of suspicions allowed us to perform an excisional biopsy which was also adequate for the primary treatment of this superficial malignant melanoma. The diagnosis, management, and followup of melanoma have undergone many changes and...

  • Production and Characterization of Tumor Infiltrating Lymphocyte Clones Derived from B16-F10 Murine Melanoma. Maeda, Kazuo; Lafreniere, Rene; Martin Jerry, L. // Journal of Investigative Dermatology;Aug91, Vol. 97 Issue 2, p183 

    The adoptive transfer of tumor infiltrating lymphocytes (TIL) in conjunction with recombinant interleukin-2 (rIL-2) for the treatment of advanced cancer has recently been under intense investigation. Despite extensive research, the precise surface phenotype of TIL remains to be fully defined. To...

  • Is 2,3,5-Pyrroletricarboxylic Acid in Hair a Better Risk Indicator for Melanoma than Traditional Epidemiologic Measures for Skin Phenotype? Stefano Rosso; Roberto Zanetti; Maria José Sánchez; Adoración Nieto; Ana Miranda; Mariette Mercier; Dora Loria; Anne Østerlind; Rüdiger Greinert; Maria-Dolores Chirlaque; Gabriella Fabbrocini; Cesare Barbera; Hélène Sancho-Garnier; Carmela Lauria; Daniela Balzi; Marina Zoccola; for the Helios Working Group // American Journal of Epidemiology;Apr2007, Vol. 165 Issue 10, p1170 

    This study aims to assess type of melanin as a risk indicator for skin tumors, in a sample of melanoma cases and controls within a larger multicenter study (Helios 2), held in Europe and South America in 2001–2002. In each case and control, the melanin content in hair was assessed by...

  • Targeted Apoptosis Activation with GrB/scFvMEL Modulates Melanoma Growth, Metastatic Spread, Chemosensitivity, and Radiosensitivity. Yuying Liu; Weihe Zhang; Ting Niu; Cheung, Lawrence H.; Munshi, Anupama; Meyn Jr., Raymond E.; Rosenblum, Michael G. // Neoplasia;Feb2006, Vol. 8 Issue 2, p125 

    GrB/scFvMEL, a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL, targets melanoma gp240 antigen and exerts impressive cytotoxic effects by inducing apoptosis. We evaluated the effects of GrB/scFvMEL on chemotherapy, radiation therapy, metastasis in vitro,...

  • Specifically targeting ERK1 or ERK2 kills Melanoma cells.  // Journal of Translational Medicine;2012, Vol. 10 Issue 1, p15 

    The article offers information on the study that examined the role of extracellular-signal-regulated kinases (ERK1) or ERK2 in killing Melanoma cells. The study directly reduced ERK1 and ERK2 using short hairpin RNAs (shRNAs) to complete inhibition of phospho-ERK (pERK). A375 melanoma cells were...

  • Updated Swiss Guidelines for the Treatment and Follow-Up of Cutaneous Melanoma. Dummer, R.; Panizzon, R.; Bloch, P. H.; Burg, G. // Dermatology (10188665);2005, Vol. 210 Issue 1, p39 

    Melanoma is the most common lethal cutaneous neoplasm. In order to harmonize treatment and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland have been inaugurated in 2001. These have been approved by all Swiss medical societies involved in the care of...

  • Neuroendocrine Carcinomas of the Lung: A Critical Analysis. Cesar Moran; Saul Suster; Domenico Coppola; Mark Wick // American Journal of Clinical Pathology;Feb2009, Vol. 131 Issue 2, p206 

    Neuroendocrine carcinomas represent an important group of primary neoplasms in the lung. During the last decades, the nomenclature of these tumors has evolved and the current use of immunohistochemical and molecular biology studies have, to some extent, expanded the conventional view of these...

  • Melanonychia Striata Longitudinalis: Multiple Benign Pigmented Streaks in a Caucasian. Goldberg, David J. // Journal of Dermatologic Surgery & Oncology;Feb86, Vol. 12 Issue 2, p188 

    Melanonychia striata, longitudinalis, or a pigmented longitudinal melanocytic streak of the nail, is distinctly uncommon in white patients. Such a finding is highly suggestive of a malignant melanoma. Reported herein is die first case report of a Caucasian with multiple pigmented streaks of the...

  • The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Millward, M. J.; House, C.; Bowtell, D.; Webster, L.; Olver, I. N.; Gore, M.; Copeman, M.; Lynch, K.; Yap, A.; Wang, Y.; Cohen, P. S.; Zalcberg, J. // British Journal of Cancer;10/9/2006, Vol. 95 Issue 7, p829 

    Midostaurin (PKC412A), N-benzoyl-staurosporine, potently inhibits protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and FLT3 tyrosine kinases. In mice, midostaurin slows growth and delays lung metastasis of melanoma cell lines. We aimed to test midostaurin's safety, efficacy and biologic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics